Intra-Cellular Therapies 관리

관리 기준 확인 2/4

Intra-Cellular Therapies CEO는 Sharon Mates, May2002 에 임명되었습니다 의 임기는 22.5 년입니다. 총 연간 보상은 $ 10.09M, 8.8% 로 구성됩니다. 8.8% 급여 및 91.2% 보너스(회사 주식 및 옵션 포함). 는 € 86.63M 가치에 해당하는 회사 주식의 1.01% 직접 소유합니다. 86.63M. 경영진과 이사회의 평균 재임 기간은 각각 6.1 년과 10.8 년입니다.

주요 정보

Sharon Mates

최고 경영자

US$10.1m

총 보상

CEO 급여 비율	8.8%
CEO 임기	22.5yrs
CEO 소유권	1.0%
경영진 평균 재임 기간	6.1yrs
이사회 평균 재임 기간	10.8yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Sharon Mates 의 보수는 Intra-Cellular Therapies 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$86m
Jun 30 2024	n/a	n/a	-US$84m
Mar 31 2024	n/a	n/a	-US$111m
Dec 31 2023	US$10m	US$892k	-US$140m
Sep 30 2023	n/a	n/a	-US$155m
Jun 30 2023	n/a	n/a	-US$184m
Mar 31 2023	n/a	n/a	-US$228m
Dec 31 2022	US$9m	US$849k	-US$256m
Sep 30 2022	n/a	n/a	-US$298m
Jun 30 2022	n/a	n/a	-US$321m
Mar 31 2022	n/a	n/a	-US$304m
Dec 31 2021	US$7m	US$794k	-US$284m
Sep 30 2021	n/a	n/a	-US$259m
Jun 30 2021	n/a	n/a	-US$237m
Mar 31 2021	n/a	n/a	-US$232m
Dec 31 2020	US$5m	US$767k	-US$227m
Sep 30 2020	n/a	n/a	-US$207m
Jun 30 2020	n/a	n/a	-US$187m
Mar 31 2020	n/a	n/a	-US$160m
Dec 31 2019	US$5m	US$745k	-US$148m
Sep 30 2019	n/a	n/a	-US$148m
Jun 30 2019	n/a	n/a	-US$155m
Mar 31 2019	n/a	n/a	-US$154m
Dec 31 2018	US$4m	US$723k	-US$155m
Sep 30 2018	n/a	n/a	-US$145m
Jun 30 2018	n/a	n/a	-US$126m
Mar 31 2018	n/a	n/a	-US$106m
Dec 31 2017	US$5m	US$702k	-US$98m

보상 대 시장: Sharon 의 총 보상 ($USD 10.09M )은 German 시장( $USD 3.38M ).

보상과 수익: 회사가 수익성이 없는 동안 Sharon 의 보상이 증가했습니다.

CEO

Sharon Mates (71 yo)

22.5yrs

테뉴어

US$10,086,413

보상

Dr. Sharon Mates, Ph.D. co-founded Intra-Cellular Therapies, Inc. (a/k/a ITI) in May 2002 and was its President until March 19, 2024. She has been Chairman and Chief Executive Officer of Intra-Cellular The...

리더십 팀

이름	위치	테뉴어	보상	소유권
Sharon Mates	Co-Founder	22.5yrs	US$10.09m	1.01% € 86.6m
Michael Halstead	President	less than a year	US$3.53m	0% € 0
Suresh Durgam	Executive VP & Chief Medical Officer	6.3yrs	US$3.51m	0.019% € 1.6m
Mark Neumann	EVP & Chief Commercial Officer	6.1yrs	US$3.54m	0.028% € 2.4m
Robert Davis	Senior VP & Chief Scientific Officer	9yrs	US$2.13m	데이터 없음
Juan Sanchez	Vice President of Corporate Communications & Investor Relations	10.7yrs	US$1.38m	데이터 없음
Karen Sheehy	Senior VP & Chief Compliance Officer	5.3yrs	데이터 없음	데이터 없음
John Condon	Senior Vice President	no data	데이터 없음	데이터 없음
Michael Olchaskey	Senior VP & Head of Regulatory Affairs	6.2yrs	데이터 없음	데이터 없음
John Bardi	Senior VP of Market Access	5.7yrs	데이터 없음	데이터 없음
Willie Earley	Senior VP & Head of Clinical Development	2.6yrs	데이터 없음	데이터 없음

6.1yrs

평균 재임 기간

61yo

평균 연령

경험이 풍부한 관리: 23I 의 관리팀은 노련하고 경험 (평균 재직 기간 6.1 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Sharon Mates	Co-Founder	11.3yrs	US$10.09m	1.01% € 86.6m
Rory Riggs	Independent Director	10.8yrs	US$470.51k	0.11% € 9.5m
Robert Van Nostrand	Lead Independent Director	10.8yrs	US$507.58k	0.011% € 918.2k
Joel Marcus	Independent Director	11.3yrs	US$473.34k	0.039% € 3.3m
Carol Tamminga	Chairman of Medical Advisory Board	no data	데이터 없음	데이터 없음
John Kane	Member of Medical Advisory Board	no data	데이터 없음	데이터 없음
Jeffrey Lieberman	Member of Medical Advisory Board	no data	데이터 없음	데이터 없음
Christoph Correll	Member of Medical Advisory Board	no data	데이터 없음	데이터 없음
Donald Goff	Member of Medical Advisory Board	no data	데이터 없음	데이터 없음
Eduardo Salas	Independent Director	2.6yrs	US$461.30k	0.0015% € 127.0k

10.8yrs

평균 재임 기간

71yo

평균 연령

경험이 풍부한 이사회: 23I 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 10.8 년).

Intra-Cellular Therapies 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Intra-Cellular Therapies, Inc., Annual General Meeting, Jun 14, 2024

Intra-Cellular Therapies, Inc. Announces Retirement of Larry Hineline as Chief Financial Officer

EVP & Chief Commercial Officer recently sold €801k worth of stock

Independent Director recently sold €240k worth of stock

Independent Director recently sold €523k worth of stock

Independent Director recently sold €523k worth of stock

Recent updates

Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating CAPLYTA for the Prevention of Relapse in Patients with Schizophrenia

Intra-Cellular Therapies, Inc. Raises Financial Guidance for the Full Year 2024

Third quarter 2024 earnings released: US$0.25 loss per share (vs US$0.25 loss in 3Q 2023)

Second quarter 2024 earnings released: US$0.16 loss per share (vs US$0.45 loss in 2Q 2023)

Intra-Cellular Therapies, Inc. Raises Sales Guidance for 2024

Intra-Cellular Therapies, Inc.(NasdaqGS:ITCI) dropped from Russell 2000 Dynamic Index

Intra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder

Intra-Cellular Therapies, Inc. Reiterates Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: US$0.16 loss per share (vs US$0.46 loss in 1Q 2023)

Intra-Cellular Therapies, Inc., Annual General Meeting, Jun 14, 2024

Intra-Cellular Therapies, Inc. has completed a Follow-on Equity Offering in the amount of $500.000068 million.

Intra-Cellular Therapies, Inc. has completed a Follow-on Equity Offering in the amount of $500.000068 million.

New minor risk - Shareholder dilution

Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder

Intra-Cellular Therapies, Inc. Announces Retirement of Larry Hineline as Chief Financial Officer

Full year 2023 earnings released: US$1.46 loss per share (vs US$2.73 loss in FY 2022)

New minor risk - Shareholder dilution

Intra-Cellular Therapies, Inc. Provides Earnings Guidance for the Full Year 2024

Forecast to breakeven in 2025

EVP & Chief Commercial Officer recently sold €801k worth of stock

Intra-Cellular Therapies, Inc. Provides Sales Guidance for the Fiscal Year 2023

Third quarter 2023 earnings released: US$0.25 loss per share (vs US$0.57 loss in 3Q 2022)

Intra-Cellular Therapies, Inc. Provides Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings released: US$0.45 loss per share (vs US$0.92 loss in 2Q 2022)

Forecast to breakeven in 2025

Intra-Cellular Therapies, Inc. Announces CAPLYTA Data Presentations At the American Society of Clinical Psychopharmacology Annual Meeting

Intra-Cellular Therapies, Inc. Reiterates Earnings Guidance for the Year 2023

First quarter 2023 earnings released: US$0.46 loss per share (vs US$0.78 loss in 1Q 2022)

Full year 2022 earnings released: US$2.73 loss per share (vs US$3.50 loss in FY 2021)

Forecast breakeven date pushed back to 2025

Forecast breakeven date pushed back to 2025

Independent Director recently sold €240k worth of stock

Independent Director recently sold €523k worth of stock

Independent Director recently sold €523k worth of stock

Third quarter 2022 earnings released: US$0.57 loss per share (vs US$0.94 loss in 3Q 2021)

Independent Director recently sold €573k worth of stock

Second quarter 2022 earnings released: US$0.92 loss per share (vs US$0.85 loss in 2Q 2021)

First quarter 2022 earnings released: US$0.78 loss per share (vs US$0.65 loss in 1Q 2021)

Intra-Cellular Therapies, Inc. Announces FDA Approval of New Dosage Strengths for CAPLYTA® (lumateperone) for Specific Patient Populations

Intra-Cellular Therapies, Inc., Annual General Meeting, Jun 09, 2022

Independent Director recently sold €736k worth of stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Forecast to breakeven in 2024

Intra-Cellular Therapies Announces U.S. FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression in Adults

Third quarter 2021 earnings released: US$0.94 loss per share (vs US$0.79 loss in 3Q 2020)

Intra-Cellular Therapies, Inc. Announces Publication of Lumateperone Pivotal Phase 3 Study in Bipolar Depression in The American Journal of Psychiatry

Second quarter 2021 earnings released: US$0.85 loss per share (vs US$0.96 loss in 2Q 2020)

Forecast to breakeven in 2023

High number of new directors

Intra-Cellular Therapies, Inc.(NasdaqGS:ITCI) dropped from Russell 3000E Value Index

First quarter 2021 earnings released: US$0.65 loss per share (vs US$0.73 loss in 1Q 2020)

Intra-Cellular Therapies Announces FDA Acceptance of Caplyta (Lumateperone) SNDAs for the Treatment of Bipolar Depression

Revenue beats expectations

Intra-Cellular Therapies Announces Expansion of Pipeline with the Introduction of New Molecular Entity, ITI-1284

Intra-Cellular Therapies Applies for FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression

New 90-day high: €32.85

New 90-day high: €29.02

Intra-Cellular Therapies, Inc. Announces the Publication of Results from the CAPLYTA Clinical Trial (ITI-007-303)

New 90-day high: €27.41

Intra-Cellular Therapies Announces the Initiation of Clinical Trials for ITI-LLAI, a Long-Acting Injectable Formulation of Lumateperone for the Treatment of Schizophrenia and for ITI-333, a Novel Treatment for Opioid Use Disorder

New 90-day high: €23.82

Senior VP of Finance recently sold €174k worth of stock

Revenue beats expectations

Intra-Cellular Therapies, Inc. Announces Executive Changes

Intra-Cellular Therapies, Inc. Announces Executive Changes

Intra-Cellular Therapies, Inc. has completed a Follow-on Equity Offering in the amount of $350.00001 million.

New 90-day low - €15.16

New 90-day low - €16.08

First half earnings released